EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKohortenstudieOpen Access · CC BY 4.0

Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study

Michiaki Abe, Takuhiro Yamaguchi, Seizo Koshiba, Shin Takayama, Toshiki Nakai, Koichiro Nishioka, Satomi Yamasaki, Kazuhiko Kawaguchi, Masanori Umeyama, Atsuko Masaura, Kota Ishizawa, Ryutaro Arita und 7 weitere

Clinical and Experimental Nephrology · 2024

DOI: 10.1007/s10157-024-02517-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Michiaki Abe und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education and Support for Regional Medicine, Tohoku University Hospital, 1-1 Seiryo-Machi, Sendai, Miyagi, 9808574, Japan. michiaki.abe…. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Oxidative Stress, Dietary Supplements, Sodium Bicarbonate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI grant, Collaborative research fund from Nippon Chemiphar Co., Ldt..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The beneficial effects of oral supplements with alkalinizing agents in patients with chronic kidney disease (CKD) have been limited to the severe stages. We investigated whether two types of supplements, sodium bicarbonate (SB) and potassium citrate/sodium citrate (PCSC), could maintain renal function in patients with mild-stage CKD.

Methods

This was a single-center, open-labeled, randomized cohort trial. Study participants with CKD stages G2, G3a, and G3b were enrolled between March 2013 and January 2019 and randomly assigned by stratification according to age, sex, estimated glomerular filtration rate (eGFR), and diabetes. They were followed up for 6 months (short-term study) for the primary endpoints and extended to 2 years (long-term study) for the secondary endpoints. Supplementary doses were adjusted to achieve an early morning urinary pH of 6.8–7.2. We observed renal dysfunction or new-onset cerebrovascular disease and evaluated urinary surrogate markers for renal injury.

Results

Overall, 101 participants were registered and allocated to three groups: standard ( n = 32), SB ( n = 34), and PCSC ( n = 35). Two patients in the standard group attained the primary endpoints (renal stones and overt proteinuria) but were not statistically significant. There was one patient in the standard reduced eGFR during the long-term study ( p = 0.042 by ANOVA). SB increased proteinuria ( p = 0.0139, baseline vs. 6 months), whereas PCSC significantly reduced proteinuria ( p = 0.0061, baseline vs. 1 year, or p = 0.0186, vs. 2 years) and urinary excretion of 8-hydroxy-2′-deoxyguanosine ( p = 0.0481, baseline vs. 6 months).

Conclusion

This study is the first to report supplementation of PCSC reduced intrarenal oxidative stress in patients with mild-stage CKD. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicOxidative StressDietary SupplementsSodium BicarbonateGlomerular Filtration RatePotassium CitrateHumansFemaleMaleMiddle AgedAgedSodium CitrateAdultAdministration, OralKidneyProteinuriaSeverity of Illness IndexHydrogen-Ion Concentration

Stichwörter der Autor:innen

AciduriaBicarbonateChronic kidney diseaseCitrateMetabolic acidosisReactive oxygen species

Substanzen

Sodium BicarbonatePotassium CitrateSodium Citrate

Autor:innen und Institutionen

  • Department of Education and Support for Regional Medicine, Tohoku University Hospital, 1-1 Seiryo-Machi, Sendai, Miyagi, 9808574, Japan. michiaki.abe.a1@tohoku.ac.jp.
  • Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan. michiaki.abe.a1@tohoku.ac.jp.
  • Department of Nephrology, Rheumatology and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. michiaki.abe.a1@tohoku.ac.jp.
  • Clinical Research Data Center, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
  • Department of Education and Support for Regional Medicine, Tohoku University Hospital, 1-1 Seiryo-Machi, Sendai, Miyagi, 9808574, Japan.

Förderung

  • JSPS KAKENHI grant
  • Collaborative research fund from Nippon Chemiphar Co., Ldt.

Zitieren

APA

Abe, M., Yamaguchi, T., Koshiba, S., Takayama, S., Nakai, T., Nishioka, K., Yamasaki, S., Kawaguchi, K., Umeyama, M., Masaura, A., Ishizawa, K., Arita, R., Kanno, T., Akaishi, T., Miyazaki, M., Abe, T., Tanaka, T., Ishii, T., & CKOALA study group (2024). Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02517-3

Vancouver

Abe M, Yamaguchi T, Koshiba S, Takayama S, Nakai T, Nishioka K, et al. Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02517-3

BibTeX
@article{Abe2024,
  author = {Abe, Michiaki and Yamaguchi, Takuhiro and Koshiba, Seizo and Takayama, Shin and Nakai, Toshiki and Nishioka, Koichiro and Yamasaki, Satomi and Kawaguchi, Kazuhiko and Umeyama, Masanori and Masaura, Atsuko and Ishizawa, Kota and Arita, Ryutaro and Kanno, Takeshi and Akaishi, Tetsuya and Miyazaki, Mariko and Abe, Takaaki and Tanaka, Tetsuhiro and Ishii, Tadashi and CKOALA study group, CKOALA study group},
  title = {Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study},
  journal = {Clinical and Experimental Nephrology},
  year = {2024},
  doi = {10.1007/s10157-024-02517-3}
}
Kostenlos starten →